SANCUSO® (Granisetron Transdermal System) is FDA indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration; some studies show that it is effective for up to 7 days. An example of such a regimen would be a 5 day course of cisplatin. SANCUSO has been studied in head and neck cancers, gastrointestinal cancers, breast cancer and gynecological cancers. It also seems particularly suited for prevention of delayed nausea and vomiting that can be seen with drugs such as cisplatin, even if not given for 5 days, that distribute into fat and then come out after 72 hours, causing nausea days after administration of chemotherapy. NCCN recommends it in its Antiemesis guidelines on p. AE-2.
Read the Professional version here